Skip to content

PTC Therapeutics

US · PTCT #2071 by market cap Listed 1970
56.42 -1.91 -3.27%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $130
    Market Newswire · 2026/8/13
  • Rating change
    J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating
    Market Newswire · 2026/10/14
  • Rating change
    A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $90 to $112
    Market Newswire · 2026/10/31
  • Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $122
    Market Newswire · 2026/11/2
  • Rating change
    Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $109
    Market Newswire · 2026/9/2
  • UBS Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $90
    Market Newswire · 2026/10/30
  • Rating change
    Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $112
    Market Newswire · 2026/10/30
  • Rating change
    RBC Capital Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $77
    Market Newswire · 2026/10/30
  • Rating change
    Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $137
    Market Newswire · 2026/9/22
  • Rating change
    Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $109
    Market Newswire · 2026/10/19
  • Rating change
    UBS Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $90
    Market Newswire · 2026/10/15
  • J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $92
    Market Newswire · 2026/11/6
  • Rating change
    Raymond James Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $106
    Market Newswire · 2026/10/20
  • Citi Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $109
    Market Newswire · 2026/11/2
  • Rating change
    RBC Capital Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Cuts Target Price to $75
    Market Newswire · 2026/10/7
  • Rating change
    BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $96
    Market Newswire · 2026/8/13
  • Rating change
    Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $122
    Market Newswire · 2026/8/14
  • Rating change
    BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating
    Market Newswire · 2026/10/9
  • Rating change
    TD Cowen Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $90
    Market Newswire · 2026/8/31
  • J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $92
    Market Newswire · 2026/11/2
  • Rating change
    Goldman Sachs Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Raises Target Price to $70
    Market Newswire · 2026/7/31
  • Rating change
    Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $106
    Market Newswire · 2026/7/31
  • Rating change
    Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120
    Market Newswire · 2026/8/4
  • Rating change
    Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $122
    Market Newswire · 2026/10/7
  • Rating change
    Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $109
    Market Newswire · 2026/8/13

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

PTC Therapeutics discussion 0 comments

Add a comment